David A. Rodeberg

Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803

Carola A.S. Arndt, Julie A. Stoner, Douglas S. Hawkins et al. · Journal of Clinical Oncology · 2009 · 363 citations · Full text

Primary Hyperparathyroidism in Pediatric Patients

Josh Kollars, Abdalla E. Zarroug, Jon van Heerden et al. · PEDIATRICS · 2005 · 253 citations

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

Brenda J. Weigel, Elizabeth Lyden, James R. Anderson et al. · Journal of Clinical Oncology · 2015 · 215 citations · Full text

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group

Douglas S. Hawkins, Yueh-Yun Chi, James R. Anderson et al. · Journal of Clinical Oncology · 2018 · 170 citations

Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group

Emily Hibbitts, Yueh‐Yun Chi, Douglas S. Hawkins et al. · Cancer Medicine · 2019 · 147 citations · Full text